Supriya Lifescience profit and loss

Latest FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026

Expenses
	873
	11.5
	884
	331
	−52.1
	102
	1.8
	30.9
	202
	615
	290
	259
Profit
	269
	−0.5
	268
	59.4
	10.4
	69.8
	198
	198
	0.8
	199
Per share
	₹24.65
	₹24.65
Other comprehensive income — detail
	0.8
	1.0
	0.3
Per share — as-filed variants
	₹24.65
	₹24.65
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	594
	68.1%
Adjusted (ex-exceptional items) — derived
	269
	−0.5
	199
	₹24.69

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUPRIYA₹869.30

Supriya Lifescience Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSTAR SPARC THYROCARE SHILPAMED VIYASH RUBICON YATHARTH PARKHOSPS

View

In ₹ Crore except Per Share 12 Months Ending	FY22 31/03/2022	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	Last 12M 30/06/2026
Revenue from Operations	—	—	—	—	872.5
Other Income	—	—	—	—	11.5
Total Income	—	—	—	—	884.0
Expenses
+ Cost of Materials Consumed	—	—	—	—	330.7
+ Changes in Inventories	—	—	—	—	-52.1
+ Employee Benefit Expense	—	—	—	—	102.5
+ Finance Costs	—	—	—	—	1.8
+ Depreciation & Amortisation	—	—	—	—	30.9
+ Other Expenses	—	—	—	—	201.6
Total Expenses	—	—	—	—	615.4
EBITDA	—	—	—	—	289.8
EBIT	—	—	—	—	258.9
Profit
PBT before Exceptional Items	—	—	—	—	268.6
+ Exceptional Items	—	—	—	—	-0.5
Pretax Income	—	—	—	—	268.2
+ Current Tax	—	—	—	—	59.4
+ Deferred Tax	—	—	—	—	10.4
Tax Expense	—	—	—	—	69.8
Net Income	—	—	—	—	198.4
+ Net Income — Continuing Ops	—	—	—	—	198.4
+ Other Comprehensive Income	—	—	—	—	0.8
Total Comprehensive Income	—	—	—	—	199.1
Per Share
Basic EPS	—	—	—	—	24.65
Diluted EPS	—	—	—	—	24.65
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	0.8
+ Items NOT to be Reclassified to P&L	—	—	—	—	1.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	0.3
Per Share — as-filed variants
Basic EPS — Continuing Operations	—	—	—	—	24.65
Diluted EPS — Continuing Operations	—	—	—	—	24.65
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	—	—	—	—	593.9
Gross Margin %	—	—	—	—	68.07
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	—	—	—	—	268.6
− Exceptional Items (reconciliation)	—	—	—	—	-0.5
Net Income Adj (tax-effected)	—	—	—	—	198.7
EPS Adj	—	—	—	—	24.69
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	—	—	—	—	2.00
Paid Up Equity Capital	—	—	—	—	16.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 89%.